Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
Clinical and Molecular Hepatology
; : 351-357, 2018.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-718639
Responsible library:
WPRO
ABSTRACT
The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Pharmacokinetics
/
Comorbidity
/
Renal Dialysis
/
Hepatitis C
/
Hepacivirus
/
Hepatitis C, Chronic
/
Renal Insufficiency, Chronic
/
Hepatitis
/
Kidney Failure, Chronic
Limits:
Humans
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2018
Document type:
Article